See how Teva Pharmaceutical Industries Limited's growth strategy and focus on specialty medicines are driving a turnaround.

Teva Pharmaceutical Industries Ltd ADR has reached a significant milestone as its stock hit a 52-week high, trading at $25.96. This achievement marks a notable recovery and growth trajectory for the ...

Teva Pharmaceutical Industries (NYSE: TEVA) had a day on the stock market to remember on Wednesday. The drugmaker 's share ...

What Happened: A Form 4 filing with the U.S. Securities and Exchange Commission on Monday outlined that Weiss executed a sale ...

Duquesne Family Office's billionaire boss has gone full contrarian by selling Wall Street's two artificial intelligence (AI) ...

Teva Pharmaceutical Industries Ltd ADR stock has reached a new 52-week high, touching 23.07 USD. This milestone reflects a significant upward trend in the company’s stock performance over the past ...

Teva shares jumped 12% after Q3 earnings beat estimates, driven by strong branded drug sales led by Austedo and solid ...

Teva Pharmaceutical (TEVA) stock surges as the company posts better than expected Q3 2025 results and raises the midpoint of ...

The Israeli pharmaceutical company, managed by CEO Richard Francis, will publish its third quarter financial results on ...

Compared to the aggregate P/E ratio of the 52.17 in the Pharmaceuticals industry, Teva Pharmaceutical Indus Inc. has a lower P/E ratio of 39.3. Shareholders might be inclined to think that the stock ...

Israel-based Phoenix Financial acquired more than 3.5 million additional shares of Teva Pharmaceuticals for an estimated $62.1 million in the third quarter. Post-transaction, the fund reported holding ...

Teva stock jumps after third-quarter earnings and revenues top estimates, driven by robust Austedo sales as well as U.S. generics growth.